Vasculitis & polymyalgia rheumatica
Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis
Authors' conclusion
Treatment of active TAK with MMF+MTX has more favourable efficacy compared to CYC/AZA.
Study context
- Population
- Adults with active TAK
- Participants
- 111 adults
- Comparison
- Oral mycophenolate mofetil (MMF) plus methotrexate (MTX) vs IV CYC followed by oral AZA, both with high-dose oral GC taper
- MMF+MTXn = 74
- CYC/AZAn = 37reference
- Primary endpoint
- Overall response rate (complete or partial response)
- Follow-up
- Week 52
Methodological details2:1 randomisation
- 2:1 randomisation
Primary result
As reported in the abstract
Overall response rate · 52 weeks
P = 0.022
Secondary outcomes
| Outcome | MMF+MTX | CYC/AZA | P value |
|---|---|---|---|
| Overall response rate · 28 weeks | 58.1% | — not stated in the abstract | P = 0.011 |
| Relapse | 4 events | 2 events |
— not stated in the abstract
Complete response (CR) and partial response (PR) rates · 28 and 52 weeks
- Also higher with MMF+MTX
Safety
- Serious adverse event (neutropenia with fever) — CYC/AZA
- 1 events
Serious adverse event (neutropenia with fever)
- One serious adverse event in total, in the CYC/AZA group
Original publication
Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis. Ann Rheum Dis. Published 22 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →